Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis.

ABSTRACT: Data regarding the efficacy and tolerability of elbasvir/grazoprevir (EBR/GZR) for East-Asian hepatitis C virus genotype 1b (HCV GT1b) patients receiving hemodialysis were limited. We prospectively recruited 40 HCV GT1b hemodialysis patients who received EBR/GZR for 12 weeks at 6 academic centers in Taiwan. The efficacy endpoints were sustained virologic response 12 weeks off-therapy (SVR₁₂) by intention-to-treat (ITT) modified ITT (mITT) analyses. Patients' baseline characteristics, early viral kinetics and HCV resistance-associated substitutions (RASs) at HCV non-structural 3 and 5 A (NS3 and NS5A) regions potentially affecting SVR₁₂ were analyzed. The tolerability for EBR/GZR was also assessed. The SVR₁₂ rates by ITT and mITT analyses were 95% (38 of 40

SUBMITTER: Liu CH 

PROVIDER: S-EPMC7280513 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature